What did the SURMOUNT-3 tirzepatide trial study — and what did it find?

Why did SURMOUNT-3 use a lifestyle run-in, and what happened during it?

Most weight-loss trials simply randomise participants at the start and measure what a medicine adds compared with a placebo. SURMOUNT-3 took a different approach. Before any medication, all participants spent 12 weeks on an intensive lifestyle intervention: a very low-calorie replacement diet combined with regular activity coaching. This was deliberate. The researchers wanted to understand what tirzepatide does for people who have genuinely committed to lifestyle change, not people who haven't tried yet.

By the end of that lead-in period, participants had lost an average of roughly 6–7% of their body weight through lifestyle alone. That baseline matters. It means the randomisation point in SURMOUNT-3 started from a lower body weight than in trials like SURMOUNT-1, where no prior intervention was required. You can read more about how that first large trial was structured on our SURMOUNT-1 overview page.

Only participants who completed the lifestyle phase and met the criteria were then randomised. That filtering step means the trial population was, in a sense, self-selected for motivation and adherence, a real-world consideration worth keeping in mind when interpreting the numbers.

What did tirzepatide actually achieve in SURMOUNT-3 compared with placebo?

After randomisation, participants either received tirzepatide (titrated from 2.5mg up to 10mg or 15mg as tolerated) or a placebo injection, both alongside continued lifestyle support. The 72-week results showed a striking difference between the two groups.

Tirzepatide participants lost substantially more weight from the randomisation point, and (critically) continued losing weight after the lifestyle phase rather than regaining it. The placebo group, by contrast, largely regained the weight they had lost during the run-in. This rebound pattern is well documented in lifestyle-only studies and reflects how biology responds when a caloric restriction is lifted without pharmacological support.

The combined effect from the start of the lifestyle programme through to the end of the medication phase produced some of the largest total weight reductions in the SURMOUNT programme. This is a meaningful finding for clinicians considering tirzepatide for patients who are already engaged in structured programmes. For a wider view of results across all the trials, the SURMOUNT weight-loss percentage summary sets the numbers in context alongside SURMOUNT-1, -2 and -4.

As with all SURMOUNT data, these results come from a controlled trial setting. Real-world outcomes vary. NICE reviewed the full evidence base when issuing its appraisal of tirzepatide (TA1026) in December 2024.

Who took part, and does SURMOUNT-3 reflect people in the UK?

SURMOUNT-3 enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition, without type 2 diabetes. That profile overlaps closely with the UK licensed eligibility criteria for tirzepatide as a weight-management medicine. The trial excluded people with a personal or family history of certain thyroid conditions, a history of pancreatitis, or certain other contraindications, the same exclusions that a UK prescriber would screen for at consultation.

The intensive lifestyle lead-in also means SURMOUNT-3 is probably the trial most relevant to people who have already tried structured diet programmes before considering medication. If that describes where you are right now, it's worth knowing the data exists specifically for that situation, you are not starting from the worst-case scenario.

SURMOUNT-3 enrolled hundreds of participants across multiple countries. For scale context, SURMOUNT-1 alone randomised 2,539 adults; the full SURMOUNT programme involved thousands across its trials. A broader look at the programme's scope is on the SURMOUNT trials overview.

What does SURMOUNT-3 tell us that the other trials don't?

Each SURMOUNT trial answers a slightly different clinical question. SURMOUNT-1 asked what tirzepatide does for adults with obesity or overweight. SURMOUNT-2 focused on adults with type 2 diabetes. SURMOUNT-4 studied what happens when treatment is stopped. SURMOUNT-3's specific contribution is answering: does tirzepatide add meaningful benefit for people who have already achieved some weight loss through intensive effort?

The answer, based on the trial data, is yes, and the benefit was substantial. The rebound seen in the placebo group underlines a point that many people find validating rather than disheartening: the difficulty of maintaining weight loss without support is a biological phenomenon, not a personal failing. Tirzepatide appears to work partly by sustaining the signals that reduce appetite and slow gastric emptying, which lifestyle change alone cannot permanently replicate. You can explore how findings like these fit into the broader evidence by reading about the tirzepatide SURMOUNT trials as a whole.

For anyone now deciding between treatment options, the tirzepatide overview covers the mechanism, the UK licence, side effects and the consultation process in full. If you're comparing tirzepatide with semaglutide, our weight-loss treatments page sets out how the two medicines differ. Tirzepatide is a prescription-only medicine; the NHS page for tirzepatide, published by NHS England, is a reliable patient-level reference for side effects, storage and interactions. A prescriber (not an algorithm) reviews every consultation at our GPhC-registered pharmacy before any treatment is issued. If you'd like that review, you can check your eligibility with a free consultation.